{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459514592
| IUPAC_name = (''E'')-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid
| image = Balsalazide structure.svg
| width = 270
<!--Clinical data-->
| tradename = Colazal, Giazo
| Drugs.com = {{drugs.com|monograph|colazal}}
| MedlinePlus = a699052
| pregnancy_US = B
| pregnancy_category =  
| legal_UK = POM
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability = <1%
| protein_bound = ≥99%
| metabolism =  
| elimination_half-life = 12hr
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 80573-04-2
| ATC_prefix = A07
| ATC_suffix = EC04
| ATC_supplemental =  
| PubChem = 5362070
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01014
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10662422
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P80AL8J7ZP
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 267413
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201346
<!--Chemical data-->
| C=17 | H=15
| N=3 | O=6
| molecular_weight = 357.318 g/mol
| smiles = O=C(O)c1cc(ccc1O)/N=N/c2ccc(cc2)C(=O)NCCC(O)=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IPOKCKJONYRRHP-FMQUCBEESA-N
}}
'''Balsalazide''' is an anti-inflammatory drug used in the treatment of [[inflammatory bowel disease]]. It is sold under the brand names '''Giazo''', '''Colazal''' in the US and '''Colazide''' in the UK. It is also sold in generic form in the US by several generic manufacturers.

It is usually administered as the disodium salt. Balsalazide releases [[mesalazine]], also known as 5-aminosalicylic acid, or 5-ASA,<ref>{{Cite journal | pmid = 11709512 | year = 2001 | last1 = Kruis | first1 = W. | last2 = Schreiber | last3 = Theuer | first3 = D. | last4 = Brandes | first4 = J. W. | last5 = Schütz | first5 = E. | last6 = Howaldt | first6 = S. | last7 = Krakamp | first7 = B. | last8 = Hämling | first8 = J. | last9 = Mönnikes | first9 = H. | last10 = Koop | first10 = I. | last11 = Stolte | first11 = M. | last12 = Pallant | first12 = D. | last13 = Ewald | first13 = U. | title = Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses | volume = 49 | issue = 6 | pages = 783–789 | journal = Gut | doi = 10.1136/gut.49.6.783| pmc = 1728533 | first2 = I.}}</ref> in the large intestine. Its advantage over that drug in the treatment of [[ulcerative colitis]] is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.

==Synthesis==
[[File:Balsalazide synthesis.png|thumb|center|600px|Balsalazide synthesis: Biorex Laboratories, {{Cite patent|GB|2080796}} (1986).]]
#Starting material is 4-amino[[hippuric acid]], obtained by coupling [[para-aminobenzoic acid]] and [[glycine]]. 
#That product is then treated with [[nitrous acid]] to give the [[diazonium salt]]. 
#Reaction of this species with [[salicylic acid]] proceeds at the position para to the phenol to give balsalazide.

==References==
{{reflist}}

{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}

[[Category:Gastroenterology]]
[[Category:Azo compounds]]
[[Category:Salicylic acids]]
[[Category:Benzamides]]
[[Category:Anilines]]
[[Category:Propionic acids]]